Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434198 | 0.90 | BRD4 (0.59) | KDM4ELMNATSHRCA1CA2 | |
| SCHEMBL70381 | 0.90 | BRD4 (0.59) | KDM4ELMNATSHRCA1CA2 | |
| SCHEMBL9300933 | 0.89 | LMNA (0.66) | KDM4ELMNATSHRCA1CA2 | |
| SCHEMBL9166724 | 0.84 | IDO1 (0.54) | KDM4ELMNATSHRMEN1MAPT | |
| SCHEMBL982076 | 0.82 | BRD4 (0.53) | KDM4ELMNATSHRBRD4MEN1 | |
| SCHEMBL5750893 | 0.82 | BRD4 (0.53) | KDM4ELMNATSHRBRD4MEN1 | |
| SCHEMBL31049726 | 0.82 | BRD4 (0.53) | KDM4ELMNATSHRBRD4MEN1 | |
| SCHEMBL31049722 | 0.82 | BRD4 (0.53) | KDM4ELMNATSHRBRD4MEN1 | |
| SCHEMBL1600050 | 0.81 | IDO1 (0.46) | KDM4ELMNATSHRMEN1MAPT | |
| SCHEMBL70429 | 0.81 | LMNA (0.59) | KDM4ELMNATSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119136797-A | CB1Ligand conjugated compounds and uses thereof | 阿达尔克斯制药有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118307518-A | Polycyclic PARP selective inhibitors | 轩竹生物科技股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-111936499-B | Heterobicyclic inhibitors of MAT2A and methods for treating cancer | 法国施维雅药厂 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023168296-A2 | CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20160289160-A1 | PRODUCTION METHOD FOR ARYL (METH) ACRYLATE | MITSUBISHI RAYON CO., LTD. (JP) | 2016-10-06 | — | — | US | disclosed |
| EP-2977367-A1 | PRODUCTION METHOD FOR (METH) ACRYLATE ARYL ESTER | Mitsubishi Rayon Co., Ltd. (JP) | 2016-01-27 | — | — | EP | disclosed |
| CN-105051000-A | Process for producing aryl (meth) acrylate | MITSUBISHI RAYON CO | 2015-11-11 | — | — | CN | disclosed |
| CN-103827121-A | oxy-cyclohexyl-4H, 6H-5-oxa-2, 3,10 b-triaza-benzo [ e ] azulenes as V1a antagonists | HOFFMANN LA ROCHE | 2014-05-28 | — | — | CN | disclosed |
| CN-101772506-B | Macrocycles and their uses | NOVARTIS AG | 2014-02-12 | — | — | CN | disclosed |
| US-8642629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-1546086-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
| WO-2004002939-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | WO | disclosed |
| US-6613942-B1 | Nonpeptide; 4-hydroxy benzoic acid hydrazides | NOVO NORDISK A/S (DK) | 2003-09-02 | — | — | US | disclosed |
| CN-1267281-A | Glucagon antagonists/inverse agonists | NOVO NORDISK AS (DK) | 2000-09-20 | — | — | CN | disclosed |
| EP-0994848-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999001423-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 1999-01-14 | — | — | WO | disclosed |
| WO-1999001423-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 1999-01-14 | — | — | WO | disclosed |
| US-5298593-A | Polymerization of ester monomer, aromatic dicarboxylic acid, and oxyaromatic carboxylic acid | MITSUBISHI PETROCHEMICAL COMPANY, LTD. (JP) | 1994-03-29 | — | — | US | disclosed |
| EP-0520428-A2 | Method of producing thermotropic liquid crystalline polyester | MITSUBISHI CHEMICAL CORPORATION (JP) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289160-A1 | PRODUCTION METHOD FOR ARYL (METH) ACRYLATE | ACR, ALK, GNPAT | KDM4E 677/4885LMNA 4763/4885TSHR 405/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | KDM4E 1554/4885LMNA 4565/4885TSHR 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.